Recombinant Factor IX Amino Acid Substitutions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemophilia B, caused by a deficiency of factor IX, are limited by high costs, frequent infusions, and risks of HIV and hepatitis transmission, with existing recombinant factor IX products offering only moderate efficacy and short half-life, and gene therapy facing obstacles such as antibody generation against delivery vehicles.
Innovation Solution
Development of a recombinant human factor IX protein with specific amino acid substitutions at positions 86, 277, and 338, which enhances clotting activity by increasing affinity for factor VIII and improving kinetic parameters, allowing for lower protein doses and longer-lasting therapeutic effects through genetic engineering and viral vector delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If plasma-derived factor IX is used for treatment, then clotting factor replacement is achieved, but risk of HIV and hepatitis transmission increases
Solution Approach 1:
The patent uses recombinant DNA technology to copy and produce factor IX protein in bacterial cells instead of using plasma-derived products. The recombinant factor IX is synthesized through genetic engineering, creating a molecular copy that eliminates the risk of viral transmission while maintaining therapeutic efficacy.
Solution Approach 2:
The patent replaces the mechanical process of plasma extraction and purification with a biochemical system involving recombinant DNA expression. The factor IX is produced through cellular metabolism in bacterial hosts, substituting the physical plasma separation process with a molecular biology-based production system.
2Ease of manufacture
If standard recombinant factor IX is used, then production cost is reduced, but clotting activity and half-life are insufficient requiring frequent infusions
Solution Approach 1:
The patent modifies specific amino acid parameters at positions 86, 277, and 338 in the factor IX protein sequence to enhance its biological properties. These parameter changes result in increased clotting activity and extended half-life, allowing for reduced infusion frequency while maintaining cost-effectiveness through recombinant production.
Solution Approach 2:
The patent creates a composite protein structure by combining the factor IX protein with specific amino acid modifications at critical positions. This composite approach integrates the base protein functionality with enhanced kinetic properties, achieving both cost reduction through recombinant production and improved therapeutic performance.
3Duration of action of stationary object
If gene therapy is used to treat hemophilia, then long-term therapeutic effect is achieved, but antibody generation against delivery vehicle occurs
Solution Approach 1:
The patent extracts and modifies the delivery vehicle components to eliminate immunogenicity. By removing or modifying the viral vector elements that trigger antibody responses, the therapy achieves long-term expression of factor IX without generating harmful antibodies against the delivery system.
Solution Approach 2:
The patent employs a non-integrating, transient expression system that does not require long-term presence of the delivery vehicle in the body. The therapeutic effect is achieved through short-term viral transduction followed by sustained protein production, eliminating the need for persistent delivery vehicles that would generate antibodies.
Data Source
AI summary
The present invention aims at converting factor IX into a molecule with enhanced activity which provides an alternative for replacement therapy and gene therapy for hemophilia B. Using recombinant techniques, factor IX with replacement at positions 86, 277, and 338 exhibits better clotting activity than recombinant wild type factor IX.